Logo

JSPR

Jasper Therapeutics, Inc.

JSPR

Jasper Therapeutics, Inc. • NASDAQ
$1.84 ▲ 5.44% (+0.10)
Market Cap $29.90 M
52w High $26.05
52w Low $1.56
Dividend Yield 0%
P/E -0.32
Volume 153.44K
Outstanding Shares 16.25M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $19.166M ▼ $-18.736M ▲ 0% $-1.13 ▲ $-18.507M ▲
Q2-2025 $0 $27.076M ▲ $-26.723M ▼ 0% $-1.74 ▼ $-26.818M ▼
Q1-2025 $0 $21.802M ▼ $-21.241M ▲ 0% $-1.41 ▲ $-21.523M ▲
Q4-2024 $0 $25.285M ▲ $-24.321M ▼ 0% $-1.62 ▼ $-25.04M ▼
Q3-2024 $0 $19.889M $-18.637M 0% $-1.24 $-19.348M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $50.899M ▲ $57.469M ▲ $45.898M ▲ $11.571M ▼
Q2-2025 $39.51M ▼ $46.466M ▼ $22.965M ▲ $23.501M ▼
Q1-2025 $48.799M ▼ $57.597M ▼ $15.353M ▼ $42.244M ▼
Q4-2024 $71.637M ▼ $79.899M ▼ $18.225M ▲ $61.674M ▼
Q3-2024 $92.502M $99.413M $15.733M $83.68M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-18.736M ▲ $-16.999M ▼ $0 ▼ $28.388M ▲ $11.389M ▲ $-16.999M ▼
Q2-2025 $-26.723M ▼ $-15.453M ▲ $1K ▼ $6.163M ▲ $-9.289M ▲ $-15.46M ▲
Q1-2025 $-21.241M ▲ $-22.842M ▼ $4K ▲ $0 ▼ $-22.838M ▼ $-22.842M ▼
Q4-2024 $-24.321M ▼ $-21.134M ▼ $-76K ▲ $345K ▲ $-20.865M ▼ $-21.23M ▼
Q3-2024 $-18.637M $-14.052M $-274K $9K $-14.317M $-14.326M

Five-Year Company Overview

Income Statement

Income Statement Jasper has essentially no product revenue yet; it’s still a pure research‑stage biotech. All of its reported results are driven by research and administrative spending, which leads to recurring operating and net losses each year. Losses have generally grown as the company has advanced its pipelines and trials, though the pace of increase has been somewhat controlled recently. The very large swings in per‑share loss mainly reflect share count changes and the reverse stock split, rather than a sudden change in the underlying business. Overall, the income statement looks typical for an early‑stage biotech: all cost, no commercial income, and ongoing red ink that will likely continue until a product is approved and launched, if that ever occurs.

Balance Sheet

Balance Sheet The balance sheet is simple and relatively clean. Assets are modest in size and are mostly cash or cash‑like instruments, with very little tied up in hard assets or equipment. The company carries no financial debt, which reduces repayment pressure but does not remove the need for future funding. Shareholders’ equity is positive but not large, and it has moved up and down as the company raises cash and then spends it on trials. The combination of a cash‑heavy, debt‑free balance sheet and a steady cash burn means the key question is how long current cash can support operations before another capital raise is needed.

Cash Flow

Cash Flow Cash flow is consistently negative, driven almost entirely by operating activities such as clinical trials, staff, and overhead. Free cash flow closely tracks operating cash flow because capital spending on equipment and facilities is minimal. Over the last few years, cash outflows have grown from small to moderate levels as development has scaled, but not explosively. This pattern is typical for a single‑asset biotech: cash raised from investors, then spent at a steady clip on research, with no offsetting inflows from product sales. Sustainability depends on the company’s ability to manage its burn rate and access fresh capital in time.

Competitive Edge

Competitive Edge Jasper’s competitive position is highly focused and narrow. Its fortunes are concentrated in a single lead drug, briquilimab, which targets a well‑defined biological pathway tied to mast cells and stem cells. This focused approach creates a potential scientific edge and a clear story, but also means the company is very exposed if trials disappoint. On the positive side, early data suggest strong and durable responses in certain allergic and urticaria conditions, with a safety profile that may avoid some side effects seen in other c‑Kit inhibitors. On the negative side, Jasper faces much larger and better‑funded competitors pursuing overlapping indications, as well as execution issues highlighted by manufacturing disruptions and trial delays. Its competitive position will depend heavily on continued strong data, reliable manufacturing, and the ability to move quickly into later‑stage trials.

Innovation and R&D

Innovation and R&D Innovation is Jasper’s main asset. Briquilimab represents a targeted, mechanistic approach aimed at the root cause of mast‑cell–driven disease rather than just symptom control. The company is trying to build a franchise around this single antibody across several conditions—chronic spontaneous urticaria, inducible urticaria, asthma, and transplant conditioning—leveraging one scientific platform into multiple potential markets. Management has shown ambition by running multiple trials in parallel, though this also stretches resources and execution capacity. Recent issues around third‑party manufacturing oversight and the need to re‑enroll some patients point to operational growing pains. Future value from R&D will hinge on confirming the early efficacy signals at higher doses and in larger, more rigorous studies, while keeping quality and timelines under control.

Summary

Jasper Therapeutics is a classic early‑stage, high‑risk biotech: no revenue, recurring losses, a cash‑dependent balance sheet, and one primary experimental drug that drives almost all of its potential. Financially, the company is burning cash at a measured but persistent pace, with no debt but a limited runway that likely requires future fundraising. Strategically, it sits on promising science in briquilimab, with encouraging early clinical results and a differentiated mechanism, but operates in a crowded field against much larger rivals and has already encountered some execution setbacks. The story is therefore binary and uncertain: considerable upside if its lead program continues to deliver in later trials and can be financed to completion, and substantial downside if data, funding, or operations fall short.

NEWS

November 22, 2025 · 11:49 PM UTC

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Read more

November 18, 2025 · 9:49 PM UTC

JSPR DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPR

Read more

November 18, 2025 · 12:05 PM UTC

DEADLINE ALERT for NX, JSPR, and KBR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Read more

November 18, 2025 · 12:00 PM UTC

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Read more

November 18, 2025 · 9:58 AM UTC

JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit

Read more